)
Visual
test
Cosmo Pharmaceuticals
Cosmo Pharmaceuticals (COPN) investor relations material
Cosmo Pharmaceuticals H2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2025 earnings summary9 Mar, 2026
Executive summary
Completed a structural transformation to a leaner, scalable, recurring revenue-focused operating model, establishing operating leverage for 2026.
Achieved €104.2M in 2025 revenue, with 85% from recurring sources, reflecting a strategic shift to predictable income streams.
EBITDA reached €9.5M, surpassing guidance, driven by operating leverage and cost discipline.
Delivered strong commercial and pipeline progress, including positive Phase 3 data for clascoterone in male hair loss and expansion of AI-enabled MedTech platforms.
Proposed €2.10 per share dividend, supported by strong liquidity and no financial debt.
Financial highlights
Total 2025 revenue reached €104.2M, with recurring revenue at €88.1M, up 15% year-over-year and representing 85% of total.
EBITDA was €9.5M, exceeding the upper end of guidance.
Closed 2025 with €128.3M in cash and zero debt; dividend maintained.
GI Genius™ recurring revenue up 211% year-over-year to €17.9M; Winlevi® up 27% to €17.2M.
Operating expenses decreased 6% year-over-year, with SG&A down 26% and R&D down 14%.
Outlook and guidance
2026 guidance: total revenue €105–110M, recurring revenue €98–102M (11–16% growth), EBITDA €10.5–13.5M (10–42% growth).
Year-end 2026 cash expected at ~€200M, with no financial debt.
R&D investment for 2026 expected at €25–30M, focused on key late-stage programs.
Vision 2030 targets recurring revenue of €260M (CAGR ~23%) from existing portfolio, up to €480M (CAGR ~39%) with new launches.
Guidance excludes potential revenues from pipeline or development-stage assets.
Clascoterone 5% partnering strategy post-data
Utilization plans for €200M projected cash
New products required for Vision 2030 upside
Clascoterone partnering and 12-month data
Upper GI software launch and US EMR integration
Takeda agreement impact on CDMO revenue
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cosmo Pharmaceuticals
- Record H1 2024 revenue and profit, led by Medtronic AI deal and strong product growth.COPN
H1 20243 Feb 2026 - Record 2024 results, robust pipeline, and global expansion drive strong growth momentum.COPNH2 20241 Dec 2025
- AI-driven MedTech, Winlevi, and Breezula fuel 39% CAGR and €480M target by 2030.COPNInvestor Day 202520 Nov 2025
- H1 2025 saw stable recurring revenues, strong Medtech AI/Derma growth, and raised guidance.COPNH1 202516 Nov 2025
Next Cosmo Pharmaceuticals earnings date
H1 202620 Jul, 2026
Cosmo Pharmaceuticals
Next Cosmo Pharmaceuticals earnings date
H1 202620 Jul, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage